1. van Duin, D, Bonomo, RA. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation β-Lactam/β-Lactamase inhibitor combinations. Clin Infect Dis 2016; 63: 234–241.
Google Scholar | Crossref | Medline2. Castanheira, M, Mills, JC, Farrell, DJ, et al. Mutation-driven β-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals. Antimicrob Agents Chemother 2014; 58: 6844–6850.
Google Scholar | Crossref | Medline3. Galani, I, Papoutsaki, V, Karantani, I, et al. In vitro activity of ceftolozane/tazobactam alone and in combination with amikacin against MDR/XDR Pseudomonas aeruginosa isolates from Greece. J Antimicrob Chemother 2020; 75: 2164–2172.
Google Scholar | Medline4. Tuon, FF, Cieslinski, J, Rodrigues, SDS, et al. Evaluation of in vitro activity of ceftolozane-tazobactam against recent clinical bacterial isolates from Brazil – the EM200 study. Braz J Infect Dis 2020; 24: 96–103.
Google Scholar | Crossref | Medline5. Karlowsky, JA, Lob, SH, Raddatz, J, et al. In vitro activity of imipenem/relebactam and ceftolozane/tazobactam against clinical isolates of gram-negative bacilli with difficult-to-treat resistance and multidrug-resistant phenotypes – SMART United States 2015–2017. Clin Infect Dis. Epub ahead of print 2 April 2020. DOI: 10.1093/cid/ciaa381.
Google Scholar | Crossref6. Jean, SS, Lu, MC, Shi, ZY, et al. In vitro activity of ceftazidime-avibactam, ceftolozane-tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART). Infect Drug Resist 2018; 11: 1983–1992.
Google Scholar | Crossref | Medline7. Karlowsky, JA, Kazmierczak, KM, Young, K, et al. In vitro activity of ceftolozane/tazobactam against phenotypically defined Extended-Spectrum β-Lactamase (ESBL)-positive isolates of Escherichia coli and Klebsiella pneumoniae isolated from hospitalized patients (SMART 2016). Diagn Microbiol Infect Dis 2020; 96: 114925.
Google Scholar | Crossref | Medline8. Mikamo, H, Monden, K, Miyasaka, Y, et al. The efficacy and safety of tazobactam/ceftolozane in combination with metronidazole in Japanese patients with complicated intra-abdominal infections. J Infect Chemother 2019; 25: 111–116.
Google Scholar | Crossref | Medline9. Arakawa, S, Kawahara, K, Kawahara, M, et al. The efficacy and safety of tazobactam/ceftolozane in Japanese patients with uncomplicated pyelonephritis and complicated urinary tract infection. J Infect Chemother 2019; 25: 104–110.
Google Scholar | Crossref | Medline10. Wagenlehner, FM, Umeh, O, Steenbergen, J, et al. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet 2015; 385: 1949–1956.
Google Scholar | Crossref | Medline | ISI11. Solomkin, J, Hershberger, E, Miller, B, et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 Trial (ASPECT-cIAI). Clin Infect Dis 2015; 60: 1462–1471.
Google Scholar | Crossref | Medline | ISI12. Kollef, MH, Nováček, M, Kivistik, Ü, et al. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 2019; 19: 1299–1311.
Google Scholar | Crossref | Medline13. Popejoy, MW, Paterson, DL, Cloutier, D, et al. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of phase 3 clinical trials. J Antimicrob Chemother 2017; 72: 268–272.
Google Scholar | Crossref | Medline14. Miller, B, Popejoy, MW, Hershberger, E, et al. Characteristics and outcomes of complicated intra-abdominal infections involving Pseudomonas aeruginosa from a randomized, double-blind, phase 3 ceftolozane-tazobactam study. Antimicrob Agents Chemother 2016; 60: 4387–4390.
Google Scholar | Crossref | Medline15. Huntington, JA, Sakoulas, G, Umeh, O, et al. Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial. J Antimicrob Chemother 2016; 71: 2014–2021.
Google Scholar | Crossref | Medline16. Chen, GJ, Pan, SC, Foo, J, et al. Comparing ceftolozane/tazobactam versus piperacillin/tazobactam as empiric therapy for complicated urinary tract infection in Taiwan: a cost-utility model focusing on gram-negative bacteria. J Microbiol Immunol Infect 2019; 52: 807–815.
Google Scholar | Crossref | Medline17. Moher, D, Shamseer, L, Clarke, M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015; 4: 1.
Google Scholar | Crossref | Medline18. Higgins, JPT, Green, S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, www.cochrane-handbook.org (2011)
Google Scholar19. DerSimonian, R, Laird, N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–188.
Google Scholar | Crossref | Medline20. Furuya-Kanamori, L, Barendregt, JJ, Doi, SAR. A new improved graphical and quantitative method for detecting bias in metaanalysis. Int J Evid Based Healthc 2018; 16: 195–203.
Google Scholar | Crossref | Medline21. Lucasti, C, Hershberger, E, Miller, B, et al. Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections. Antimicrob Agents Chemother 2014; 58: 5350–5357.
Google Scholar | Crossref | Medline | ISI22. Cheng, IL, Chen, YH, Lai, CC, et al. The use of ceftolozane-tazobactam in the treatment of complicated intra-abdominal infections and complicated urinary tract infections-a meta-analysis of randomized controlled trials. Int J Antimicrob Agents 2020; 55: 105858.
Google Scholar | Crossref | Medline23. Chen, M, Zhang, M, Huang, P, et al. Novel β-lactam/β-lactamase inhibitors versus alternative antibiotics for the treatment of complicated intra-abdominal infection and complicated urinary tract infection: a meta-analysis of randomized controlled trials. Expert Rev Anti Infect Ther 2018; 16: 111–120.
Google Scholar | Crossref | Medline24. Maraolo, AE, Mazzitelli, M, Trecarichi, EM, et al. Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: a systematic review of its efficacy and safety for off-label indications. Int J Antimicrob Agents 2020; 55: 105891.
Google Scholar | Crossref | Medline